Patent US4012712A successfully refreshed from Google Patents.
US5399352A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Device for local drug delivery and methods for using the same
Assignee: Emory University
•
Filing: 1993-04-14
•
Granted: 1995-03-21
•
Expires: 2013-04-14
Abstract
Abstract A device for the local delivery of a substance into a natural tissue conduit in the mammalian body, having a first clement capable of contacting the lumen of the conduit and a second element which overlays first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit such that a substance placed in the reservoir is delivered into the conduit. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.
Inventors
- 👤 Stephen R. Hanson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 23:20
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2/064; A61M; A61M25/00; A61M25/0021; A61M37/00; A61F2250/00; A61F2250/0058; A61F2250/0067; A61M25/0043; A61M2025/0063; A61M25/0041
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
140 words
A device for the local delivery of a substance into a natural tissue conduit in the mammalian body, comprising: a) a first element comprised of a biocompatible material which can be affixed to the conduit and having a first surface, an opposite second surface, and an intermediate porous portion which communicates the second surface with the first surface, wherein the first surface of the porous portion can be placed in fluid communication with the lumen of the conduit; and b) a second element comprised of a substantially non-porous biocompatible material which overlays the second surface of the first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit via the porous portion such that a substance in the reservoir is delivered into the conduit.
Claim 2
Independent Claim
140 words
A device for the local delivery of a substance into a natural tissue conduit in the mammalian body, comprising: a) a first element comprised of a biocompatible material which can be affixed to the conduit and having a first surface, an opposite second surface, and an intermediate porous portion which communicates the second surface with the first surface, wherein the first surface of the porous portion can be placed in fluid communication with the lumen of the conduit; and b) a second element comprised of a substantially non-porous biocompatible material which overlays the second surface of the first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit via the porous portion such that a substance in the reservoir is delivered into the conduit.
Claim 3
Dependent Claim
19 words
The device of claim 1, wherein the first element forms a patch which overlies a portion of the conduit.
Claim 4
Dependent Claim
20 words
The device of claim 1, wherein the conduit is a blood vessel and the first element is a vascular patch.
Claim 5
Dependent Claim
64 words
The device of claim 1, wherein the first element further comprises an elongated tubular segment having a substantially non-compliant, hollow body portion which is open at both ends wherein the first surface is the luminal surface of the tubular segment, and wherein the tubular segment is capable of being affixed to the natural tissue conduit at both of the ends of the tubular segment.
Claim 6
Dependent Claim
20 words
The device of claim 4, wherein the conduit is a blood vessel and the first element is a tubular prosthesis.
Claim 7
Dependent Claim
18 words
The device of claim 4, wherein the first element forms a tubular vascular prosthesis with a blood vessel.
Claim 8
Dependent Claim
30 words
The device of claim 1, further comprising a tube in communication at its first end with the reservoir and at its second end with a remote source of the substance.
Claim 9
Dependent Claim
41 words
The device of claim 7, further comprising a pump connected to the second end of the tube for delivering a substance to the reservoir and for creating pressure within the reservoir which exceeds the intraluminal pressure of the natural tissue conduit.
Claim 10
Dependent Claim
22 words
The device of claim 1, wherein the first element comprises material selected from the group consisting of biocompatible polymers, metals and ceramics.
Claim 11
Dependent Claim
19 words
The device of claim 9, wherein the polymer is selected from the group consisting of fluoropolymer, polyurethane, and polyester.
Claim 12
Dependent Claim
19 words
The device of claim 9, wherein the polymer is selected from the group consisting of polyethylene terephthalate and polytetrafluoroethylene.
Claim 13
Dependent Claim
32 words
The device of claim 1, further comprising a coating on a portion of the first surface in contact with the lumen of the conduit which improves the biocompatibility of the first surface.
Claim 14
Dependent Claim
23 words
The device of claim 8 wherein the coating is selected from the group consisting of silicone rubber, fluorocarbon, hydrocarbon, and polyurethane based polymers.
Claim 15
Dependent Claim
24 words
The device of claim 1, wherein the second element is comprised of material selected from the group consisting of biocompatible polymers, metals and ceramics.
Claim 16
Dependent Claim
24 words
The device of claim 14, wherein the polymer is selected from the group consisting of silicone rubber, polyurethane, polyfluorocarbon, polyethylene, polycarbonate and polyvinyl chloride.
Claim 17
Dependent Claim
11 words
The device of claim 1, wherein the substance is a drug.
Claim 18
Dependent Claim
11 words
The device of claim 1, wherein the substance is an anticoagulant.
Claim 19
Dependent Claim
35 words
The device of claim 17, wherein the anticoagulant is selected from the group consisting of heparin, hirudin, hirulog, hirugen, activated and non-activated protein C, antagonists of thrombin, Factor Xa and activated and non-activated coagulation factors.
Claim 20
Dependent Claim
14 words
The device of claim 1, wherein the substance antagonizes platelet deposition and thrombus formation.
Claim 21
Dependent Claim
53 words
The device of claim 19, wherein the substance is selected from the group consisting of plasmin, tissue plasminogen activator (tPA), urokinase (UK), single chain prourokinase (scuPA), streptokinase, prostaglandins, cyclooxygenase inhibitors, phosphodiesterase inhibitors, thromboxane synthetase inhibitors, antagonists of glycoprotein receptors including (GP) Ib,GP IIb/IIIa, antagonists of collagen receptors, and antagonists of platelet thrombin receptors.
Claim 22
Dependent Claim
12 words
The device of claim 1, wherein the substance affects platelet metabolic function.
Claim 23
Dependent Claim
30 words
The device of claim 21, wherein the substance is selected from the group consisting of prostaglandins, cyclooxygenase inhibitors, phosphodiesterase inhibitors, thromboxane inhibitors, inhibitors of calcium transport, and cyclic AMP agonists.
Claim 24
Dependent Claim
14 words
The device of claim 1, wherein the substance prevents restenosis of a blood vessel.
Claim 25
Dependent Claim
61 words
The device of claim 21, wherein the substance is selected from the group consisting of a growth factor, a growth factor inhibitor, growth factor receptor antagonist, transcriptional repressor, translational repressor, antisense. DNA, antisense RNA, replication inhibitor, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules comprising a growth factor and a cytotoxin, and bifunctional molecules comprising an antibody and a cytotoxin.
Claim 26
Dependent Claim
11 words
The device of claim 1, wherein the substance is a vasodilator.
Claim 27
Dependent Claim
31 words
The device of claim 23, wherein the substance is selected from the group consisting of prostaglandins, thromboxane antagonists, nitroglycerin, nitroprusside, agents which liberate nitric oxide, and agents which inhibit calcium transport.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-03-20 | 1998-09-19 | 1999-03-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-03-20 | 2002-09-19 | 2003-03-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-03-20 | 2006-09-19 | 2007-03-21 | $7700.00 | Window Closed / Lapsed |